Ikonisys reports full-year 2023 results

Ikonisys (EPA:ALIKO) Full Year 2023 Results

Key Financial Results

• Net loss: EUR 2.27 million (loss reduced by 7.4% compared to fiscal year 2022).

All numbers shown in the chart above are for the last 12 months (TTM)

Ikonisys Profit Insight

Revenues are forecast to grow by an average of 47% per year over the next three years, while the medical equipment industry in France is forecast to grow by 5.6%.

Efficiency French medical equipment industry.

The company’s shares were up 1.4% from the previous week.

Risk assessment

We should say that we have discovered 3 warning signs for Ikonisys (1 doesn’t quite suit us!) what you should know before investing here.

Have an opinion on this article? Concerned about the content? contact us with us directly. You can also email us at editorial-team (at) simplywallst.com.

This Simply Wall St article is for general information purposes only. Our commentary is based solely on historical data and analyst forecasts, and is based on an objective methodology. Our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or your financial situation. Our goal is to provide you with long-term, focused analysis based on fundamental data. Please note that our analysis may not reflect the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Contact us directly. Alternatively, send an email to [email protected]